A new decade: novel immunotherapies on the horizon for relapsed/refractory multiple myeloma

被引：8

作者：

Braunstein, Marc ^{[1
]}

Weltz, Jonathan ^{[2
]}

Davies, Faith ^{[3
]}

机构：

[1] NYU, Long Isl Sch Med, Dept Med, Div Oncol Hematol, New York, NY USA

[2] NYU, Perlmutter Canc Ctr, New York, NY USA

[3] NYU, Grossman Sch Med, Div Hematol Oncol, Dept Med, New York, NY USA

来源：

EXPERT REVIEW OF HEMATOLOGY | 2021年 / 14卷 / 04期

关键词：

Multiple myeloma; immunotherapies; monoclonal antibodies; antibody-drug conjugates; bispecific antibodies; car-t cells; T-CELL THERAPY; OPEN-LABEL; TUMOR MICROENVIRONMENT; MONOCLONAL-ANTIBODIES; PLUS POMALIDOMIDE; PD-1; BLOCKADE; DARATUMUMAB; DEXAMETHASONE; MULTICENTER; BCMA;

D O I：

10.1080/17474086.2021.1909469

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Introduction Survival in multiple myeloma (MM) has improved due to the ongoing revolution of therapeutic approaches. Nevertheless, many patients relapse, and additional novel approaches are required to prolong remissions and prevent disease progression. Areas Covered Considering the success of monoclonal antibodies (mAbs) against CD38 and SLAMF7 in relapsed/refractory MM (R/R MM), additional antigens expressed on malignant plasma cells are being investigated as treatment targets. Among these, many trials are focusing on B cell maturation antigen (BCMA), using either antibody-drug conjugates (ADCs), bispecific T cell engagers (TCE), or chimeric antigen receptor T cells (CAR-T). Other potential targets include the myeloma markers CD138, GPRC5D, FcRH5, the plasma cell differentiating factors APRIL, TACI and BAFF, and the immune checkpoint proteins CD47 and TIGIT. Additionally, novel immunomodulatory Cereblon E3 Ligase Modulators (CELMoDs) offer the potential to overcome resistance to conventional immunomodulatory agents. Based upon PubMed and abstract searches primarily from the past 4 years, here we review the data supporting novel immunotherapies for R/R MM. Expert opinion Overcoming disease resistance remains a challenge in R/R MM. Novel therapeutic approaches targeting MM antigens and/or enhancing immune cell function offer the potential to prolong survival and are actively being investigated in clinical trials.

引用

页码：377 / 389

页数：13

共 105 条

[1]

Al-Homsi S., 2020, BLOOD, V136

[2] Re-challenging with anti-CD38 monotherapy in triple-refractory multiple myeloma patients is a feasible and safe approach [J].

Alici, Evren ;

Chrobok, Michael ;

Lund, Johan ;

Ahmadi, Tahamtan ;

Khan, Imran ;

Duru, Adil D. ;

Nahi, Hareth .

BRITISH JOURNAL OF HAEMATOLOGY, 2016, 174 (03) :473-477

[3] Updated Results from the Phase I CRB-402 Study of Anti-Bcma CAR-T Cell Therapy bb21217 in Patients with Relapsed and Refractory Multiple Myeloma: Correlation of Expansion and Duration of Response with T Cell Phenotypes [J].

Alsina, Melissa ;

Shah, Nina ;

Raje, Noopur S. ;

Jagannath, Sundar ;

Madduri, Deepu ;

Kaufman, Jonathan L. ;

Siegel, David S. ;

Munshi, Nikhil C. ;

Rosenblatt, Jacalyn ;

Lin, Yi ;

Jakubowiak, Andrzej ;

Jasielec, Jagoda ;

Timm, Alison ;

Turka, Ashley ;

Mao, Pingping ;

Martin, Nathan ;

Campbell, Timothy B. ;

Hege, Kristen ;

Bitter, Hans ;

Petrocca, Fabio ;

Berdeja, Jesus G. .

BLOOD, 2020, 136

[4] Pembrolizumab, pomalidomide, and low-dose dexamethasone for relapsed/refractory multiple myeloma [J].

Badros, Ashraf ;

Hyjek, Elizabeth ;

Ma, Ning ;

Lesokhin, Alexander ;

Dogan, Ahmet ;

Rapoport, Aaron P. ;

Kocoglu, Mehmet ;

Lederer, Emily ;

Philip, Sunita ;

Milliron, Todd ;

Dell, Cameron ;

Goloubeva, Olga ;

Singh, Zeba .

BLOOD, 2017, 130 (10) :1189-1197

[5] Iberdomide (CC-220) is a potent cereblon E3 ligase modulator with antitumor and immunostimulatory activities in lenalidomide- and pomalidomide-resistant multiple myeloma cells with dysregulated CRBN [J].

Bjorklund, Chad C. ;

Kang, Jian ;

Amatangelo, Michael ;

Polonskaia, Ann ;

Katz, Mark ;

Chiu, Hsiling ;

Couto, Suzana ;

Wang, Maria ;

Ren, Yan ;

Ortiz, Maria ;

Towfic, Fadi ;

Flynt, J. Erin ;

Pierceall, William ;

Thakurta, Anjan .

LEUKEMIA, 2020, 34 (04) :1197-1201

[6] T Cells Genetically Modified to Express an Anti-B-Cell Maturation Antigen Chimeric Antigen Receptor Cause Remissions of Poor-Prognosis Relapsed Multiple Myeloma [J].

Brudno, Jennifer N. ;

Maric, Irina ;

Hartman, Steven D. ;

Rose, Jeremy J. ;

Wang, Michael ;

Lam, Norris ;

Stetler-Stevenson, Maryalice ;

Salem, Dalia ;

Yuan, Constance ;

Pavletic, Steven ;

Kanakry, Jennifer A. ;

Ali, Syed Abbas ;

Mikkilineni, Lekha ;

Feldman, Steven A. ;

Stroncek, David F. ;

Hansen, Brenna G. ;

Lawrence, Judith ;

Patel, Rashmika ;

Hakim, Frances ;

Gress, Ronald E. ;

Kochenderfer, James N. .

JOURNAL OF CLINICAL ONCOLOGY, 2018, 36 (22) :2267-+

[7] TAK-169, a Novel Recombinant Immunotoxin Specific for CD38, Induces Powerful Preclinical Activity Against Patient-Derived Multiple Myeloma Cells [J].

Bruins, Wassilis S. C. ;

Zheng, Wenrou ;

Higgins, Jack P. ;

Willert, Erin K. ;

Newcomb, John ;

Dash, Ajeeta B. ;

Van de Donk, Niels W. C. J. ;

Zweegman, Sonja ;

Mutis, Tuna .

BLOOD, 2020, 136

[8] A Phase 1, First-in-Human Study of Talquetamab, a G Protein-Coupled Receptor Family C Group 5 Member D (GPRC5D) x CD3 Bispecific Antibody, in Patients with Relapsed and/or Refractory Multiple Myeloma (RRMM) [J].

Chari, Ajai ;

Berdeja, Jesus G. ;

Oriol, Albert ;

van de Donk, Niels W. C. J. ;

Rodriguez, Paula ;

Askari, Elham ;

Mateos, Maria-Victoria ;

Minnema, Monique C. ;

Verona, Raluca ;

Girgis, Suzette ;

Prior, Thomas ;

Hilder, Brandi W. ;

Russell, Jeffery ;

Goldberg, Jenna D. ;

Krishnan, Amrita .

BLOOD, 2020, 136

[9] Daratumumab plus pomalidomide and dexamethasone in relapsed and/or refractory multiple myeloma [J].

Chari, Ajai ;

Suvannasankha, Attaya ;

Fay, Joseph W. ;

Arnulf, Bertrand ;

Kaufman, Jonathan L. ;

Ifthikharuddin, Jainulabdeen J. ;

Weiss, Brendan M. ;

Krishnan, Amrita ;

Lentzsch, Suzanne ;

Comenzo, Raymond ;

Wang, Jianping ;

Nottage, Kerri ;

Chiu, Christopher ;

Khokhar, Nushmia Z. ;

Ahmadi, Tahamtan ;

Lonial, Sagar .

BLOOD, 2017, 130 (08) :974-981

[10] Bone marrow-derived mesenchymal stem cells promote cell proliferation of multiple myeloma through inhibiting T cell immune responses via PD-1/PD-L1 pathway [J].

Chen, Dandan ;

Tang, Ping ;

Liu, Linxiang ;

Wang, Fang ;

Xing, Haizhou ;

Sun, Ling ;

Jiang, Zhongxing .

CELL CYCLE, 2018, 17 (07) :858-867

← 1 2 3 4 5 6 7 8 9 10 →